Novartis Announces $23 Billion Investment to Expand API Manufacturing Facility in North Carolina
Introduction
Novartis has announced plans to develop a new 56,200-square-foot manufacturing facility in Morrisville, North Carolina, as part of its wider $23 billion investment in US-based manufacturing and research.
The facility will focus on producing active pharmaceutical ingredients (APIs) for solid dosage forms, such as tablets and capsules, as well as RNA therapeutics.
Features
The facility is designed to enhance domestic manufacturing capacity and support the development of future therapies.
It will enable the production of APIs for tablets, capsules and RNA-based medicines, while reinforcing integrated, end-to-end manufacturing within the US.
The expansion will increase Novartis’s footprint in North Carolina to five facilities across three sites and support both current treatments and next-generation therapies.
In addition, the facility aligns with the company’s broader strategy to advance multiple technology platforms, including radioligand therapies, RNA therapeutics, and cell and gene therapies, while contributing to the localisation of key medicine production for US patients.
This expansion strengthens the end-to-end production in the U.S., from raw materials to finished medicines, and improves patient access to innovative treatments.
Specifications
| Name | Novartis |
| Budget | $23 Billion |
| Type | Expansion |
